Ropes & Gray represented Teva Pharmaceuticals International GmbH in the deal. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced...
Teva Pharmaceuticals’ Licensing Agreement with mAbxience
Blackstone Life Sciences’ $750 Million Collaboration with Moderna
Ropes & Gray represented Blackstone Life Sciences in the transaction. Blackstone Life Sciences (NYSE:BX) (“Blackstone”) announced a collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and...
Solid Biosciences’ Licensing Agreement with Armatus Bio
Ropes & Gray advised Solid Biosciences on the transaction. Solid Biosciences (Nasdaq: SLDB), a biotechnology company specializing in genetic medicines for neuromuscular and cardiac diseases, announced...
AbbVie’s Collaboration with Umoja Biopharma
Ropes & Gray advised AbbVie on the deal. AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja) Umoja Biopharma announced two exclusive option and license agreements to develop multiple in-situ...
ImmunoGen’s Collaboration with Takeda
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited (TSE:...
Verastem Oncology’s Collaboration with GenFleet Therapeutics
Ropes & Gray advised Verastem Oncology on the deal. Verastem Oncology (Nasdaq: VSTM) announced that the company has entered into a discovery and development collaboration with...
ImmunoGen’s Multi-Target License and Option Agreement with ImmunoBiochem
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation on the...
STERIS’ $540 Million Acquisition of BD’s Surgical Instrumentation Platform
Thompson Hine advises STERIS, and Ropes & Gray advises Becton, Dickinson and Company on the deal. STERIS plc (NYSE: STE) announced that the company has signed...
Ovid Therapeutics’ Collaboration with Graviton Bioscience
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a collaboration with Graviton Bioscience Corporation under which Ovid obtained exclusive rights to develop...
Xeris Biopharma’s Research Collaboration with Regeneron Pharmaceuticals
Ropes & Gray represented Xeris Biopharma Holdings on the deal. Xeris Biopharma Holdings announced a platform research evaluation, collaboration and option agreement with Regeneron Pharmaceuticals, Inc....
ImmunoGen’s Global Multi-Target License and Option Agreement with Vertex
Ropes & Gray represented ImmunoGen, Inc. on the deal. ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, announced a global, multi-target license and option agreement...
Amarin’s License and Distribution Agreement with CSL Seqirus
Ropes & Gray represented Amarin Corporation plc on the deal. Pharmaceutical company Amarin Corporation plc announced an agreement with CSL Seqirus for an exclusive license and distribution...